• MyoScience

  Participated · Series D · Mar 2012

  Myoscience develops a platform technology called focused cold therapy (FCT) for treating conditions involving nerves. FCT is approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction, treatment of dermatologic conditions and focal cryo‑treatment of tissue, and has been cleared in the United States for pain management and general surgical use. The company plans to use proceeds from its recent financing to commercialize its first indication in Europe: a treatment to reduce dynamic facial lines (forehead wrinkles). Myoscience is led by President & CEO Clint Carnell and is based in Redwood City, California. The company is also working to raise a second tranche of up to $12M in addition to the Series D.

• Aethon

  Participated · Equity · Apr 2010

  Aethon develops TUG® smart autonomous mobile robots and MedEx™ software to automate intralogistics in hospitals, delivering and tracking medication, meals, linen, equipment and supplies. The company launched commercially in 2004 and has deployed over 400 TUG robots performing more than 50,000 deliveries each week across U.S. hospitals. Aethon positions its solutions to improve safety, security and efficiency while freeing clinical staff for direct patient care. It plans to expand its U.S.-based sales force, increase marketing, and grow business development efforts in foreign markets with support from strategic investors. Aethon has received capital from corporate backers and venture firms, including Mitsui USA, the Bosch Group and Trident Capital. Aethon is a developer of autonomous mobile robots and accompanying logistics and tracking software for hospitals, selling its TUG robots and the MedEx medication tracking/delivery system. The company launched into the commercial market in 2005 and is based in Pittsburgh. Nearly 400 TUG robots have been deployed across 135 hospitals, collectively logging more than 50,000 deliveries each week. TUGs transport medication, meals, linens, equipment, supplies and lab specimens, and Aethon positions its platform as a technology-based logistics solution to improve safety and efficiency. The company plans geographic expansion, citing discussions into Europe following a 2010 strategic partnership with the Bosch Group and exploring Asian markets with support from new investor Mitsui USA. Financially, Aethon announced $7.1 million in growth capital in its latest round, part of which came from Mitsui & Co. (USA) Inc. Aethon develops mobile robotics for hospital supply chain logistics, offering departmental and hospital-wide applications that automate the movement of goods such as medications, supplies, meals, and equipment. Its systems aim to improve asset utilization and ensure regulatory compliance. The company recently raised $6.6M to accelerate sales expansion and new product development. Bosch will support engineering efforts as Aethon adds product extensions and scales production capabilities. Aethon is pursuing opportunities to embed its technology in the global healthcare marketplace as it commercializes hospital logistics automation.

• Lab21

  Participated · Equity · Jan 2009

  Lab21 develops and manufactures molecular and immunodiagnostic products and provides clinical laboratory services for personalised medicine, blood bank screening and other clinical diagnostics. The company operates two divisions: a Clinical Laboratories division that develops molecular diagnostic services and companion diagnostics for oncology and infectious diseases, and a Products division that manufactures infectious disease tests such as malaria, Chagas, syphilis and cytomegalovirus (CMV) for blood screening. Lab21's customers include major pharmaceutical companies, diagnostic manufacturers, clinical laboratories and biotechnology firms. The company has corporate offices in Cambridge, UK and Greenville, South Carolina, and manufacturing/GMP capacity in Cambridge with additional facilities in Newmarket, Camberley and Bridport. Lab21 follows a buy-and-build strategy, is a rapidly growing molecular and immunodiagnostics manufacturer, and was expected to deliver greater than 30% revenue growth in 2012. The company plans to expand GMP manufacturing capability and to grow its international sales channel, particularly into the U.S. Lab21 provides state-of-the-art diagnostic products and services, supporting drug discovery and healthcare, with its clinical reference laboratory and corporate office in Cambridge, UK. Its growing test portfolio offers companion diagnostics and high-technology assays in infectious diseases, oncology and pharmacogenetics, with emerging interests in cardiovascular and metabolic disease. The company announced it has closed a £2.2m round of financing from international private equity investors. New investors Nexus Medical Partners and Rowan Dartington join existing shareholders Merlin Biosciences and Kreos Capital, and Dr Ed Snape of Nexus will join Lab21's board. Lab21 said the funds will be used to progress an acquisition plan and to establish US operations in South Carolina to expand its presence in the North American market. The company expects to complete two European company acquisitions during the first half of next year.

No current team members are available.